Therapeutic Potential of RNA Interference in Pain Medicine

Ping-Heng Tan*, 1, Lin-Cheng Yang1, Ru-Rong Ji2
1 Department of Anesthesiology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan
2 Pain Research Center,Department of Anesthesiology, Brigham and Women’s Hospital and Harvard Medical School, 75 Francis Street,Medical Research Building, Room 604, Boston, Massachusetts 02115, USA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 135
Abstract HTML Views: 333
PDF Downloads: 158
Total Views/Downloads: 626
Unique Statistics:

Full-Text HTML Views: 106
Abstract HTML Views: 211
PDF Downloads: 127
Total Views/Downloads: 444

© 2009 Tan et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Anesthesiology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan; Tel: 886-7-3477902; Fax: 886-7-3423348; E-mail: E-mail:


In recent years RNA interference (RNAi) has rapidly become the most widely used tool for gene knockdown due to its high specificity and potency. RNAi is an evolutionarily conserved mechanism for silencing gene expression by targeted degradation of mRNA. In the past decade, hundreds of molecular targets have been identified for their roles in pain modulation. But most molecular targets are not readily druggable with small molecules. RNAi represents a therapeutic approach applicable to these non-druggable targets. There is a rapid increase in the number of studies that use small interfering RNAs (siRNAs) to validate new targets for pain regulation. In this review, we will discuss these painrelated RNAi studies (Table 1). We will also compare the advantages and disadvantages of RNAi with antisense knockdown (Table 2), because antisense oligodeoxynucleotides have been extensively used for target validation in pain research. Although in vivo delivery of siRNA remains to be a challenge, RNAi has a great potential to become a major therapeutic tool for pain management.